Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 9 | 2020 | 2887 | 0.390 |
Why?
|
| Quality of Life | 3 | 2020 | 1583 | 0.210 |
Why?
|
| Health Care Surveys | 1 | 2002 | 278 | 0.210 |
Why?
|
| Fatigue | 1 | 2002 | 174 | 0.210 |
Why?
|
| Anemia | 1 | 2002 | 128 | 0.210 |
Why?
|
| Mortality | 1 | 2002 | 149 | 0.190 |
Why?
|
| Capecitabine | 1 | 2020 | 96 | 0.180 |
Why?
|
| Flow Cytometry | 2 | 1992 | 679 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 236 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 199 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 1801 | 0.150 |
Why?
|
| Patient Care Planning | 1 | 2015 | 81 | 0.130 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2012 | 40 | 0.130 |
Why?
|
| Neoplasms | 2 | 2015 | 2897 | 0.120 |
Why?
|
| Self Care | 1 | 2015 | 164 | 0.120 |
Why?
|
| Health Promotion | 1 | 2015 | 160 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 1464 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 202 | 0.110 |
Why?
|
| Radioisotope Teletherapy | 1 | 1992 | 4 | 0.110 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1992 | 6 | 0.110 |
Why?
|
| Cobalt Radioisotopes | 1 | 1992 | 19 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 351 | 0.110 |
Why?
|
| Spectrophotometry | 1 | 1992 | 106 | 0.110 |
Why?
|
| Aromatase Inhibitors | 1 | 2012 | 28 | 0.110 |
Why?
|
| Arthralgia | 1 | 2012 | 36 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 2357 | 0.100 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1990 | 111 | 0.090 |
Why?
|
| Health Status | 1 | 2011 | 360 | 0.090 |
Why?
|
| Carcinoma | 1 | 1992 | 436 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2004 | 2436 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 2501 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2006 | 135 | 0.070 |
Why?
|
| Female | 11 | 2020 | 44507 | 0.070 |
Why?
|
| Middle Aged | 8 | 2020 | 25017 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6501 | 0.060 |
Why?
|
| DNA | 1 | 1990 | 1294 | 0.060 |
Why?
|
| Receptor, ErbB-3 | 1 | 2004 | 18 | 0.060 |
Why?
|
| Aged | 6 | 2020 | 18402 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 223 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2015 | 1313 | 0.050 |
Why?
|
| Prognosis | 3 | 2020 | 3674 | 0.050 |
Why?
|
| Adult | 6 | 2020 | 25640 | 0.050 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 26 | 0.050 |
Why?
|
| Ploidies | 2 | 1990 | 40 | 0.050 |
Why?
|
| Humans | 11 | 2020 | 86601 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 3636 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 1376 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 329 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 1992 | 1685 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2006 | 481 | 0.040 |
Why?
|
| Transitional Care | 1 | 2015 | 18 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1850 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2011 | 1937 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2015 | 181 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2004 | 1538 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 226 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 169 | 0.030 |
Why?
|
| United States | 2 | 2004 | 6665 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2006 | 1204 | 0.030 |
Why?
|
| Risk Factors | 2 | 2015 | 5416 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 299 | 0.030 |
Why?
|
| Androstadienes | 1 | 2012 | 72 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2356 | 0.030 |
Why?
|
| Nitriles | 1 | 2012 | 149 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 4210 | 0.030 |
Why?
|
| Doxorubicin | 1 | 1992 | 295 | 0.030 |
Why?
|
| Outpatients | 1 | 2012 | 94 | 0.030 |
Why?
|
| Triazoles | 1 | 2012 | 96 | 0.030 |
Why?
|
| Fluorouracil | 1 | 1992 | 556 | 0.020 |
Why?
|
| Male | 3 | 2015 | 40956 | 0.020 |
Why?
|
| History, 20th Century | 1 | 1992 | 312 | 0.020 |
Why?
|
| Oncogenes | 1 | 1989 | 88 | 0.020 |
Why?
|
| Axilla | 1 | 1989 | 97 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 1990 | 384 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1989 | 286 | 0.020 |
Why?
|
| Cell Division | 1 | 1989 | 696 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2011 | 359 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2012 | 8475 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1576 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2011 | 7988 | 0.020 |
Why?
|
| Carcinoma, Lobular | 1 | 2006 | 80 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1989 | 530 | 0.020 |
Why?
|
| Body Weight | 1 | 2006 | 459 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2006 | 156 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2006 | 860 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 857 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2004 | 68 | 0.010 |
Why?
|
| Taxoids | 1 | 2004 | 129 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 5974 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1989 | 1458 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 348 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 712 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 1197 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2004 | 930 | 0.010 |
Why?
|